Clinical Trial Update: Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating tislelizumab combined with chemoradiotherapy and surgery for unresectable esophageal squamous cell carcinoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Ming-Yu Lien | Conditions: Esophageal Squamous Cell Carcinoma (ESCC), Locally Advanced Unresectable Esophageal Cancer | Phase 2 | Status: RECRUITING